Compare Illumina, Inc. (ILMN) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Nerdwallet Inc — how do they compare? Illumina, Inc. trades at $190.68 (market cap $29.12B), while Nerdwallet Inc trades at $9.54 (market cap $625.17M). The key difference: Illumina, Inc. is far larger — about 46.6× Nerdwallet Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | NRDS | |
|---|---|---|
Market Cap | $29.12B | $625.17M |
Sector | Health | Financials |
52-Week High | $205.10 | $15.93 |
52-Week Low | $91.00 | $7.58 |
Enterprise Value | $30.48B | $539.47M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
NRDS trades at $9.76, down 0.41% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue of $197 million, up 6% year-over-year, though EPS missed estimates. Valuation ratios appear attractive with a P/E of 10.87 and P/S of 0.81, while profitability metrics like an 18.16% ROE and 93.5% gross margin remain strong. Recent news highlights analyst optimism for a 27.9% upside potential.
The outlook is positive due to solid fundamentals and growth in personal loans and deposit accounts, offsetting SEO pressures. Risks include execution in shifting business models and competitive threats. With 66.7% of analysts rating it Buy and a consensus bullish stance, the stock presents a growth opportunity amid manageable risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
